904 related articles for article (PubMed ID: 31384886)
21. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
22. The National Cancer Screening Program for breast cancer in the Republic of Korea: is it cost-effective?
Kang MH; Park EC; Choi KS; Suh M; Jun JK; Cho E
Asian Pac J Cancer Prev; 2013; 14(3):2059-65. PubMed ID: 23679319
[TBL] [Abstract][Full Text] [Related]
23. Colonoscopies in Australia - how much does the National Bowel Cancer Screening Program contribute to colonoscopy use?
Worthington J; He E; Lew JB; St John J; Horn C; Grogan P; Canfell K; Feletto E
Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36477980
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
25. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline.
Helsingen LM; Vandvik PO; Jodal HC; Agoritsas T; Lytvyn L; Anderson JC; Auer R; Murphy SB; Almadi MA; Corley DA; Quinlan C; Fuchs JM; McKinnon A; Qaseem A; Heen AF; Siemieniuk RAC; Kalager M; Usher-Smith JA; Lansdorp-Vogelaar I; Bretthauer M; Guyatt G
BMJ; 2019 Oct; 367():l5515. PubMed ID: 31578196
[TBL] [Abstract][Full Text] [Related]
26. Screening for cancer in low- and middle-income countries.
Sankaranarayanan R
Ann Glob Health; 2014; 80(5):412-7. PubMed ID: 25512156
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
O'Leary BA; Olynyk JK; Neville AM; Platell CF
J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
[TBL] [Abstract][Full Text] [Related]
28. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
29. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
Kang YJ; Killen J; Caruana M; Simms K; Taylor N; Frayling IM; Snowsill T; Huxley N; Coupe VM; Hughes S; Freeman V; Boussioutas A; Trainer AH; Ward RL; Mitchell G; Macrae FA; Canfell K
Med J Aust; 2020 Feb; 212(2):72-81. PubMed ID: 31595523
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of Korea's National Cervical Cancer Screening Program.
Cho E; Kang MH; Choi KS; Suh M; Jun JK; Park EC
Asian Pac J Cancer Prev; 2013; 14(7):4329-34. PubMed ID: 23991998
[TBL] [Abstract][Full Text] [Related]
32. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.
Pignone MP; Flitcroft KL; Howard K; Trevena LJ; Salkeld GP; St John DJ
Med J Aust; 2011 Feb; 194(4):180-5. PubMed ID: 21401458
[TBL] [Abstract][Full Text] [Related]
33. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
34. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
Sharp L; Tilson L; Whyte S; O'Ceilleachair A; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
Br J Cancer; 2012 Feb; 106(5):805-16. PubMed ID: 22343624
[TBL] [Abstract][Full Text] [Related]
36. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
[TBL] [Abstract][Full Text] [Related]
37. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.
Mezei AK; Pedersen HN; Sy S; Regan C; Mitchell-Foster SM; Byamugisha J; Sekikubo M; Armstrong H; Rawat A; Singer J; Ogilvie GS; Kim JJ; Campos NG
BMJ Open; 2018 Jun; 8(6):e020484. PubMed ID: 29895648
[TBL] [Abstract][Full Text] [Related]
38. Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.
Sharp L; Tilson L; Whyte S; Ceilleachair AO; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
BMC Health Serv Res; 2013 Mar; 13():105. PubMed ID: 23510135
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]